ImmunoCellular Therapeutics, Ltd.
IMUC
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.83M
Close$
$-0.01
110.4% downside
Current Fair Value
110.4% downsideOvervalued by 110.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.83 Million |
|---|---|
| Enterprise Value | $27.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 0.17 |
| Outstanding Shares | 113,270,751 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -14.47 |
|---|---|
| PEG | 14.47 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -50.67 |
| Enterprise Value to Net Income | -60 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ImmunoCellular Therapeutics, Ltd.
3 employees
CEO: Dr. Irach B. Taraporewala B.S., M.S., Ph.D. Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is...